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ABSTRACT
Objective: The resurgence of tuberculosis (TB) caused by Mycobacterium TB (MTB) is associated with the rapid spread of multidrug-resistant, 
therefore, the development of new antimycobacterial agents is necessary. The aim of this study was to evaluate the antimycobacterial activity of 
ursolic acid (UA) when it using alone and combination with TB drugs.
Methods: MTB H37Rv strain, streptomycin-rifampicin resistant strain, and isoniazid-ethambutol resistant strain were evaluated by susceptibility test 
using a serial number of UA (25-150 µg/mL). Minimum inhibitory concentration (MIC) was read as minimum concentration of drugs that completely 
inhibit visible growth of organism. Activities of drug combination of UA with TB drug were determined in Lowenstein-Jensen media by calculating 
the fractional inhibitory concentration index.
Results: The results showed that MIC of UA was 50 µg/mL against three different strains of MTB. The combination of UA and TB drugs displayed 
synergistic interaction, and no antagonism result from the combination was observed for strains of MTB.
Conclusion: These results indicate that UA may serve as a promising lead compound for future antimycobacterial drug development.
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INTRODUCTION
Tuberculosis (TB) is the world’s second most common cause of death 
by infectious disease. It has been estimated that one-third of the 
world’s population is infected with Mycobacterium TB (MTB) and 10% 
of these people will become active patients during their lifetime [1]. 
The situation is getting worse day by day owing to the emergence of 
multidrug-resistant (MDR) TB strains and its association with human 
immunodeficiency virus or acquired immunodeficiency syndrome 
renders its control more difficult. In 2014, 4800,000 people developed 
MDR TB in the world and 1.9% of TB cases with MDR-TB in Indonesia [2]. 
Thus, there is an urgent need to discover new anti-TB agents that are 
effective in TB treatment not only new synthetic drugs but also natural 
products are potential sources of new antimycobacterial products.
Ursolic acid (UA) is pentacyclic triterpenoid which considered as 
ubiquitous triterpenoids in the plant kingdom. It has low solubility 
in water and high lipophilicity [3]. This triterpene is quite interesting 
because it demonstrated variety biological effects such as anti-
inflammation, hepatoprotection, antihyperglycemia, and antitumor 
promotion [4]. Research conducted by López-García et al. [5] shown 
that UA causes a decrease in the growth and development of MTB in 
macrophages, stimulates the production of nitric oxide in the early 
phase, and stimulate to suppress transforming growth factor-alpha 
(TGF-α) and TGF-β. In addition, dichloromethane extract Duroia 
macrophylla which contained UA showed a significant reduction 
of activity in rats induced by MTB H37Rv sensitive strain and MDR 
strain [6]. Meanwhile, synergistic interaction of UA when it is used 
combination with the first-line anti-TB drugs is still unclear.
This study investigated the in vitro antimycobacterial activity of 
UA against three different strains of MTB (H37Rv sensitive strain, 
streptomycin-rifampicin (RMP) resistant strain, and isoniazid-
ethambutol resistant strain) when is used as individual and combination 
with first-line anti-TB drugs. Minimum inhibitory concentration (MICs) 
values and fractional inhibitory concentration (FICIs) were used in 
order to assess the synergistic activity of UA.
METHODS
Reagents and antibiotics
UA was purchased from Bio Basic Canada Inc. Markham Ontario, 
Canada. It was dissolved in dimethyl sulfoxide (DMSO) (Merck) as 
a solvent. The antibiotics RMP, isoniazid (INH), streptomycin (STR), 
and ethambutol (EMB) were purchased from Sigma-Aldrich. INH, STR, 
and EMB were prepared in deionized water, and RMP was prepared in 
dimethylformamide (Merck). DMSO was used as an appropriate solvent 
control with the concentration of 0.5% v/v [7].
Microorganism
The antimycobacterial activity was evaluated using MTB H37Rv 
sensitive strain, streptomycin-RMP resistant strain, and isoniazid-
ethambutol resistant strain. All bacterial strains were provided from 
Balai Pengembangan Laboratorium Kesehatan Provinsi Jawa Barat. 
Bacterial strains were maintained by subculture on Ogawa 3% favorable 
to their growth for 3 weeks at 37°C.
Determination of antimycobacterial susceptibility in vitro
The antimycobacterial activities of UA and INH, RMP, STR, and EMB 
against three different type of MTB were tested by susceptibility test using 
proportion method in Lowenstein-Jensen (LJ) media. The inoculum was 
adjusted to 3×106 cfu/mL by comparison with Mc. Farland no.1 turbidity 
standard and 100 µl bacterial suspension containing approximately 3×105 
cfu/mL were spotted onto LJ media in Mc Cartney tubes. Cultivation was 
done at 37°C for 8 weeks, and MICs were read as minimum concentrations 
of drugs completely inhibiting visible growth of the organism.
Activities of drug combinations
The effects of combinations of UA and anti-TB drugs (STR, RMP, INH, or 
EMB) were determined as described as determination of MICs. 1/8, ¼, 
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and ½ of MIC UA and anti-TB drugs were combined and tested in LJ 
media using susceptibility test. Interpretation data were achieved by 







Interpretation data of FICI of the results as follows: FICI ≤0.5, synergis; 
FICI 0.5-4, no interaction; FICI >4.0; antagonism.
RESULTS
Antimycobacterial susceptibility in vitro
The MICs of UA was determined according to susceptibility test using 
proportion method as described in methods. MIC of MTB in different 
strains is showed in Table 1. According to that data, it can be shown that 
UA can inhibit the growth of MTB in all different strains at concentration 
50 µg/mL.
STR, INH, RMP, and EMB were used as drug control in determining 
MIC of UA and anti-TB drugs. The antimycobacterial susceptibility test 
results showed that H37Rv strain is sensitive to all anti-TB drugs used in 
this study. RMP-streptomycin resistant strain was found to be resistant 
to both RMP and STR, and isoniazid-ethambutol resistant strain was 
showed to be resistant to both INH and EMB.
Combination testing
The results of the combination of UA with STR, INH, RMP, EMB, or 
all first-line drugs of anti-TB are listed in Table 2. The MIC for anti-
TB drugs used in this combination study are streptomycin 4 µg/mL, 
isoniazid 0.2 µg/mL, RMP 40 µg/mL, and ethambutol 2 µg/mL. The 
combination of UA and STR, INH, RMP, EMB, and all first-line drugs of 
TB showed synergistic activity with FICI values ≤0.5. No interaction 
was found when UA in combination with STR or RMP against RMP-
streptomycin resistant strains but the synergistic effect was showed 
when UA combined with INH, EMB, or all first-line drugs. No interaction 
result was also found when UA combined with INH and EMB against 
isoniazid-ethambutol resistant strains, but the synergistic interaction 
was also showed as the result of the combination UA with STR, RMP, 
and all first-line drugs. The MICs of UA against drug-sensitive strain 
and drug-resistant strains are significantly decreased ranging from 
6.25 to 25 µg/mL and also the MICs of anti-TB drugs, respectively. The 
FICI values were showed ranging from 0.25 to 0.5 and some of the 
combination found to have FICI values of 1. Noticeably, no antagonism 
result from the combination of UA with anti-TB drugs observed for any 
of the strains tested.
DISCUSSION
Until now, the treatment for this infection needs three to five different 
drugs simultaneously, depending on the patient category. These anti-
TB drugs can be given as single-drug formulations or as fixed-dose 
combination formulations where two or more anti-TB drugs are 
present in fixed proportions in the same formulation [8]. Each of the 
anti-TB drugs has a major role in killing of MTB. For example, INH is the 
most widely used first-line anti-TB drugs. This bactericidal activity has 
critical early in therapy which rapidly reduces the sputum viable count 
because it is active mainly against the organisms growing aerobically in 
pulmonary cavities [9]. RMP is important in killing organisms that are 
metabolizing slowly, killing the persisters, and sterilizing the patient’s 
sputum [10]. EMB is the first-line drug that is used in combination with 
INH and RMP. EMB is a bacteriostatic that interferes the biosynthesis of 
cell wall arabinogalactan [11]. Streptomycin is an alternative first-line 
anti-TB drug recommended by WHO. This aminocyclitol glycoside has 
been demonstrated to take place at the ribosomal level [12].
Treatment of drug resistant in MTB has become a major problem 
worldwide and more serious because of the resistant fenomena. 
The cell wall hydrophobicity of MTB naturally prevents diffusion 
and binding of many drugs. Moreover, this mycobacterium has many 
efflux pumps which contribute to expel the drugs rapidly before they 
enter to the site action [13]. Based on that fenomena, development 
of new antimycobacterial agent becomes necessary. UA is pentacyclic 
triterpenes that widely found in several plants and reported to have 
many activities. Several studies showed that pentacyclic triterpenes to 
be responsible for the antimycobacterial activity.
UA (3β-hydroxy-urs- 12-en-28-oic acid) is an isomer from oleanolic 
acid (OA) (3β-hydroxy-olea-12-en-28-oic acid) which differs in the 
position of a methyl residue attached to position 19 or 20 of the cyclic 
ring system (Fig. 1). They are pentacyclic triterpenes in the form of 
free acid or aglycones for triterpenoid saponin [14]. Study conducted 
by Wójciak-Kosior [15] reported that these compounds have similar 
Table 1: MICs of UA against drug‑sensitive and drug‑resistant 
strains of Mtb
Properties Strain of Mycobacterium tuberculosis 
MIC±standard deviation (µg/mL)






UA 50±0 50±0 50±0
SD: Standard deviation; in vitro MIC values are the means±standard deviation, 
n=3, MIC: Minimum inhibitory concentration, UA: Ursolic acid
Table 2: Combination testing of UA and antituberculosis drugs against different strains of Mycobacterium tuberculosis
Drug combination Status of strains Combination MICs±standard deviation (µg/mL) FICIs Conclusion
UA/STR H37Rv S 6.25/0.5±0 0.25 Sy
RSR 25/2±0 1 N
HER 6.25/0.5±0 0.25 Sy
UA/INH H37RvS 6.25/0.025±0 0.25 Sy
RSR 6.25/0.025±0 0.25 Sy
HER 25/0.1±0 1 N
UA/RMP H37RvS 6.25/5±0 0.25 Sy
RSR 25/20±0 1 N
HER 12.5/10±0 0.5 Sy
UA/EMB H37RvS 12.5/0.5±0 0.5 Sy
RSR 6.25/0.25±0 0.25 Sy
HER 25/1±0 1 N
UA/STR/ H37RvS 6.25/0.5/0.025/5/0.25±0 0.25 Sy
INH/ RSR 6.25/0.5/0.025/5/0.25±0 0.25 Sy
RMP/EMB HER 6.25/0.5/0.025/5/0.25±0 0.25 Sy
SD: Standard deviation; in vitro MIC values are the means±Standard deviation, n=3; S: Sensitive, R: Resistant, RS: Rifampicin-streptomycin, HE: Isoniazid-ethambutol, 
N: No interaction, Sy: Synergistic, STR: Streptomycin, EMB: Ethambutol, INH: Isoniazid, RMP: Rifampicin, UA: Ursolic acid, MIC: Minimum inhibitory concentration
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Rf values which make it difficult to separate in medicinal plants. In 
addition, UA and OA also have similar chemical structure that makes 
them have similar characteristic in pharmacology properties [16,17].
Many studies reported that UA and OA can inhibit the growth and 
survival of many bacteria, including pathogen one. Study literature data 
reported that OA, other pentacyclic triterpenes, has a synergistic effect 
when it combined with INH, RMP, or EMB [18]. Another study showed 
that UA and OA found to have synergistic activity. Intracellular activity 
of these two compounds can inhibit the growth of mycobacteria at low 
doses [16].
The synergistic effects from UA and anti-TB drugs indicated that the 
antimycobacterial combinations were more effective than the activity 
of the individual agents. The decrease of MIC value resulting from the 
combinations indicated the improved bactericidal potentials of UA 
and the anti-TB drugs as combined antimycobacterial agents. The high 
lipophilicity of pentacyclic triterpenes is probably the main factor that 
allows their penetration through the mycobacterial cell wall [18,19]. 
Acids from UA affected cell morphology and enhanced autolysis of 
the bacterial cells. UA also can inhibit peptidoglycan turnover and 
affected the profile of muropeptides after digestion of peptidoglycan 
with mutanolysin [20]. Another study showed that the mechanism of 
antimicrobial action of UA has been investigated and found to be based 
on the inhibition of DNA polymerase [21]. In addition, triterpenes UA 
was found relatively non-toxic [13].
CONCLUSION
From this study, we can see that combination of UA and first-line anti-
TB drugs showed significant potential for the development of new 
antimycobacterial agent and reduction of drug resistance. Reducing the 
dose of STR, INH, RMP, and EMB as the result of combining them with 
UA hopefully can reduce the side effect caused by these anti-TB drugs. 
These results are preliminary but are of sufficient interest to warrant 
further study and indicate that UA is worthy of further investigation as 
a template for the development of novel antimycobacterial compounds. 
More study are needed on molecular basis of the synergistic interaction 
to understand the synergistic mechanism. For further study, we will 
evaluate the mechanism of action in docking molecular and in vivo 
testing of drug efficacy using genetic tools against MTB.
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